RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, released the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development and bringing with it an unprecedented step-change in quantifiable productivity metrics. RoosterVial™-hUC-MSC-XF, allows scientists to generate billions of perinatal cells in a fraction of the time when paired with RoosterBio’s existing xeno-free (XF) hMSC plug and play systems. This product line is the only commercially available, high-volume perinatal MSC bioprocess system with a line of sight to towards clinical translation. [Read more…]
What are Placental Stem Cells? | What are Placental Stem Cells Used For?
What are placental stem cells and what are placental stem cells used for? As placental stem cells get explored for a variety of therapeutic applications, these questions become increasingly important. The opportunity to collect placental stem cells is also a once in a lifetime opportunity. [Read more…]
Cord Blood Market Consolidation in Latin America
In this interview with James Alexis Mendez, we discuss the market strategy of CryoHoldco, a stem cell bank holding company that is the market leader in Latin America and one of the ten largest cord blood banks in the world. James Alexis Mendez currently serves as the CFO and Board member of CryoHoldco.
Approaching 200,000 stem cell units in storage, CryoHoldco is more than 5X larger than any other stem cell bank in Latin America.
CryoHoldco owns the cord blood market leaders in both Mexico and Colombia, and plans to expand into other regions of Latin America. In this interview, we discuss the current and future state of cord blood banking within Latin America, Cryoholdco’s role within this evolving marketplace, and future directions for the company.
Prior to initiating the consolidation strategy of CryoHoldco with ACON Investments, Alexis was a Director of TCP Latam, a private equity and restructuring fund in Brazil. Prior to TCP Latam, he was a senior associate at Long Point Capital, a leveraged-buyout private equity fund in New York, where Alexis was responsible for equity investments in excess of USD $100 million in several private companies.
Americord Registry Introduces Placental Tissue 2.0™ Amniotic Membrane Biobanking for Families
New York, NY July 2019 – Americord Registry announced today the launch of its newest stem cell banking product, Placental Tissue 2.0TM. Americord was one of the first family cord blood banks to store placental tissue and now offers this exciting product, which stores live amniotic membrane (AM), a first for the industry. [Read more…]
Cellara, LLC, releases CultureTrax, Productivity Software Designed for the Unique Complexities of Stem Cell Research
Productivity software enables tracking, sharing and collaborating around stem cell research to accelerate scientific discoveries and breakthroughs.
Madison, WI, June 3, 2019 — Cellara, LLC, a software-as-a-service company, announced the commercial release of CultureTrax software V2.0. It is the first productivity software designed to meet the unique needs of stem cell scientists.
Stem cells are a core technology for basic biological and medical research as well as the foundation of rapidly emerging cell-based therapies and disease models for drug development. Discoveries are built on stem cell scientists’ ability to communicate quickly and accurately with one another and reproduce their own work or the work of others. Studies indicate more than 50% of published pre-clinical biology research cannot be easily reproduced (Freedman, et al, 2015).
Outdated methods for documenting experimental details and sharing protocols using static documents and paper lab notebooks are a major source of the problem. Although many labs are adopting electronic lab notebooks, these have not solved the complex cell line tracking and reproducibility challenges unique to stem cell research.
“Our vision is to accelerate scientific discoveries and breakthrough therapies by providing advanced cell culture software,” says CEO Scott Fulton. “CultureTrax software enables you to quickly and easily plan and fully document your cell culture and analytical work. The software also provides a repository for detailed, current protocols and recipes, structured to drive accurate execution in the lab and rapid, comprehensive recording of results.”
Professor Rebekah Gundry of Medical College of Wisconsin has been using CultureTrax software in her lab for two years, and states, “CultureTrax provides immediate, paperless access to protocols, recipes and the experimental plan which minimizes human error and saves us time.”
CultureTrax is a secure web-based application, so you can access your work from anywhere through a browser on your PC or tablet. CultureTrax enables you to easily share both your experimental workload, your protocols and your detailed results with colleagues. This improves the ability of scientists to replicate work and enhance efficiency and progress in the field of stem cell research. For more information, visit www.culturetrax.com.
About Cellara
Cellara is a software-as-a-service company that has developed CultureTrax, a powerful stem cell productivity platform capable of managing the complex needs of stem cell research. It is a Wisconsin-based company headquartered in Madison, a world-class center of the most advanced cell culture science, life science tools industry and information technology. CultureTrax creates a common digital language to empower cell culture scientists to realize the full potential of their research and collaborate more effectively.
Do you have questions about Cellara or its CultureTrax software V2.0? Ask them in the comments below.
